Personalized mRNA vaccine cuts melanoma's return by 42% in a large trial
Published
In 1,137 patients whose melanoma had been surgically removed, adding Moderna and Merck's custom-made vaccine to Keytruda lowered the risk of the cancer coming back or death. After two years, 82% were cancer-free versus 70% on Keytruda alone. Full results are being presented this weekend. The vaccine is not yet approved and is available only in clinical trials.
Source: AJMC
This is a plain-language summary. Read the original source for full details.